Association of the Transthyretin Variant V122I With Polyneuropathy Among Individuals of African Descent

Margaret M. Parker, PhD; Scott M. Damrauer, MD; Catherine Tcheandjieu, PhD; David Erbe, PhD; Emre Aldinc, MD; Philip N. Hawkins, PhD; Julian D. Gillmore, PhD; Leland E. Hull, MD; Julie A. Lynch, PhD; Jacob Joseph, MD; Simina Ticau, PhD; Alexander O. Flynn-Carroll, MRes; Aimee M. Deaton, PhD; Lucas D. Ward, PhD; Themistocles L. Assimes, MD; Philip S. Tsao, PhD; Kyong-Mi Chang, MD; Daniel J. Rader, MD; Kevin Fitzgerald, PhD; Akshay K. Vaishnaw, PhD; Gregory Hinkle, PhD; Paul Nioi, PhD

Author Affiliations: Alnylam Pharmaceuticals, Cambridge, USA (Parker, Erbe, Aldinc, Ticau, Flynn-Carroll, Deaton, Ward, Fitzgerald, Vaishnaw, Hinkle, Nioi); Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Damrauer); The Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA (Damrauer, Chang); 12 VA Palo Alto Health Care System, Palo Alto, CA, USA (Tcheandjieu, Assimes, Tsao); Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA (Tcheandjieu, Assimes, Tsao); Centre for Amyloidosis & Acute Phase Proteins, Division of Medicine UCL (Royal Free Campus), London, UK (Hawkins, Gillmore); Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA (Hull); Center for Healthcare Organization and Implementation Research, Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, USA (Hull); School of Nursing & Health Sciences, University of Massachusetts, Boston, MA, USA (Lynch); VA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System, Salt Lake City, UT, USA (Lynch); Department of Medicine,

Veterans Affairs Boston Healthcare System, Boston, MA, USA (Joseph); Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA (Joseph); Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Chang, Rader); Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Rader).

Corresponding Author: Paul Nioi, PhD, Alnylam Pharmaceuticals, 300 3rd St., Cambridge, MA 02142, USA (pnioi@alnylam.com).

BACKGROUND

Hereditary transthyretin-mediated (hATTR) amyloidosis is a progressively debilitating disease caused by transthyretin (*TTR*) gene mutations. The V122I variant, a common pathogenic *TTR* mutation found primarily in individuals of West African descent, is frequently associated with cardiomyopathy.

METHODS

The association between the V122I variant and ICD10 diagnosis codes was assessed in the UK Biobank black subpopulation (N=6062); whether significant associations could be replicated in the Penn Medicine Biobank (N=5737) and Million Veteran Program (N=82,382) was then investigated. Cumulative incidence of common hATTR amyloidosis manifestations (polyneuropathy, carpal tunnel syndrome, cardiomyopathy, and heart failure) was estimated by V122I genotype in the UK Biobank using Cox regression controlling for age, sex, and genetic ancestry.

RESULTS

Phenome-wide analysis identified a significant association between V122I genotype and polyneuropathy diagnosis (odds ratio [OR]=6.4, 95% confidence interval [CI]=2.6–15.6, P=4.2×10^{-5}) in the UK Biobank. A significant association was also observed in the Penn Medicine Biobank (OR=1.6, 95% CI=1.2–2.4, P=6.0×10^{-3}) and the Million Veteran Program (OR=1.5, 95% CI=1.2–1.8, P=1.8×10^{-4}). Prevalence of a polyneuropathy diagnosis among V122I carriers was 2.1%, 9.0%, and 4.8% in the UK Biobank, Penn Medicine Biobank, and Million Veteran Program, respectively. In the UK Biobank, common hATTR amyloidosis manifestations were significantly enriched in V122I carriers compared with non-carriers (HR=2.8; 95% CI=1.7–4.5; P=2.6×10^{-5}). By

age 75, 37.4% of V122I carriers had a diagnosis of any one of the common manifestations, including polyneuropathy (7.9%).

CONCLUSIONS

V122I carriers, historically associated with a predominantly cardiac phenotype of hATTR amyloidosis, have a significantly increased risk of polyneuropathy.

Introduction

Hereditary transthyretin-mediated (hATTR) amyloidosis, also known as ATTRv amyloidosis, is an underdiagnosed, progressively debilitating, and fatal disease caused by mutations in the transthyretin (*TTR*) gene. These pathogenic variants result in misfolding of TTR proteins which accumulate as amyloid deposits in multiple tissues throughout the body, including the heart, nerves, and gastrointestinal tract.[1-3] Organ involvement and symptoms of hATTR amyloidosis can vary by patient and mutation, but carriers of pathogenic variants have an increased risk of developing life-impacting polyneuropathy, cardiomyopathy, and other symptoms (eg, carpal tunnel syndrome [CTS]).[4,5]

One of the most common pathogenic *TTR* variants is the valine-to-isoleucine substitution at position 122 (V122I; p.V142I; rs76992529), which is predominantly found in individuals of West African descent,[6] with 3%-4% of this population carrying the mutation.[7] The variant was originally identified in cardiac TTR amyloid deposits,[8] and subsequent studies demonstrated it as a common cause of heart failure (HF) among elderly African patients.[9,10] V122I hATTR amyloidosis is substantially underdiagnosed,[5] and patients are often at an advanced disease stage when finally diagnosed. This long journey to diagnosis also results in poor outcomes for these patients, with median time from diagnosis to death being 2.6 years.[9] Thus, a better understanding of early hATTR amyloidosis disease manifestations is critical to expedite diagnosis and initiate treatment.[11] Unlike some other common *TTR* mutations, the V122I variant has historically been associated with a predominantly cardiac phenotype. However, a better understanding of the full range of disease manifestations associated with

this variant is critical to improve disease recognition and allow maximal benefit from currently available therapies.

The present study assessed the association of the V122I genotype with ICD10 (International Statistical Classification of Diseases and Related Health Problems, 10th Revision) disease diagnoses in the UK Biobank, a large population-based prospective cohort study.[12] The UK Biobank study does not recruit participants based on any disease outcome, thus affording the unique opportunity to analyze the V122I variant in a population not influenced by referral bias, allowing better understanding of early disease manifestations and variant penetrance. Significant associations were assessed for replication in the Penn Medicine Biobank and Million Veteran Program.

Methods

Study Populations

The UK Biobank recruited ~500 000 participants in England, Wales, and Scotland between 2006 and 2010.[13] The Penn Medicine Biobank includes over 60 000 participants over age 18 enrolled through the University of Pennsylvania Health System since 2008. The Million Veteran Program is a large multi-ethnic cohort within the United States Department of Veterans Affairs (VA) which includes more than 825 000 veterans over age 18 who have been recruited since 2011 across the United States. This study included 6062 unrelated Black participants of the UK Biobank, defined based on a combination of self-report and genetic ancestry, as well as data from 5737 Black participants from the Penn Medicine Biobank[5] and 82 382 Black participants

from the Million Veteran Program.[14] Written informed consent was obtained from all participants. A detailed description of the contributing cohorts is provided in the Supplementary eAppendix.

V122I Genotyping

The V122I genotype was directly typed by the UK Biobank on either the UK BiLEVE or the UK Biobank Axiom arrays[15] (info score = 1). Additional genotyping details are provided in the Supplementary eAppendix. Patients with and without the V122I genotype are referred to as "carriers" and "non-carriers," respectively. The presence/absence of other *TTR* genotypes was not examined in these populations.

Statistical Analysis

Descriptive statistics are presented as means (standard deviations) for continuous variables and percentages for categoric variables. Continuous and categoric variables were compared between V122I carriers and non-carriers using a t-test and a Pearson's chi-squared test, respectively.

Phenome-Wide Association Analysis and Replication

To identify diagnoses associated with the V122I variant, a phenome-wide association analysis (PHEWAS) was performed on any primary or secondary inpatient ICD10 diagnosis code observed in at least 15 Black participants from the UK Biobank (n = 427 ICD10 codes). PHEWAS was performed in PLINK[16] using logistic regression controlling for age, sex, and genetic ancestry

via 10 principal components. A Bonferroni-corrected $P = 1.2 \times 10^{-4}$ was considered statistically significant. Significant associations with ICD9 and/or ICD10 diagnoses were assessed for replication in the Penn Medicine Biobank and Million Veteran Program using logistic regression controlling for age, sex, and genetic ancestry. Additional methodologic details are provided in the Supplementary eAppendix.

Assessment of Common hATTR Amyloidosis Manifestations in V122I Carriers

A variable was created to indicate if UK Biobank participants had been diagnosed with at least 1 of 4 common hATTR amyloidosis manifestations, independent of whether the participants had a diagnosis of hATTR amyloidosis, using the following ICD10 codes: polyneuropathy ("G62"), CTS ("G560"), cardiomyopathy ("I42"), and HF ("I50" or "I098"), hereafter termed "common hATTR amyloidosis manifestations." The association between the V122I genotype and a diagnosis of a common hATTR amyloidosis manifestation was tested using logistic regression and Cox proportional hazards regression controlling for age, sex, and genetic ancestry; $P < .05$ was considered statistically significant. Kaplan–Meier curves were used to estimate cumulative incidence of common hATTR amyloidosis manifestations by V122I genotype (additional methodologic details in the Supplementary eAppendix).

Characteristics of V122I Carriers With Common hATTR Amyloidosis Manifestations

V122I carriers with at least 1 common hATTR amyloidosis manifestation were compared with V122I carriers without manifestations using logistic regression, controlling for baseline age, sex, body mass index, cigarette smoking status, and genetic principal components.

Population Attributable Risk of Common hATTR Amyloidosis Manifestations to the V122I Genotype

The population risk of common hATTR amyloidosis manifestations attributable to the V122I genotype was calculated by multiplying the fraction of all diagnoses in V122I carriers by the risk difference between carriers and non-carriers. Risk was estimated using the cumulative incidence of the manifestations at age 75 for V122I carriers and non-carriers (additional methodologic details are described in eAppendix1 in the Supplement).

Results

Baseline Characteristics

A total of 387 of 487 327 genotyped UK Biobank participants carried the V122I variant, of which 80.6% were of self-reported African descent (eFigure 1 in the Supplement). Analyses were performed in the unrelated Black UK Biobank population (n = 6062), which included 240 heterozygotes and 3 homozygotes for the V122I variant (minor allele frequency = 2.0% or 1 in 50). Characteristics of this population are listed in Table 1. On average, participants were followed up for 7.6 years (range: 0.22-10.0 years) and were 59.6 years old at censoring (range: 42.2-79.0 years) (eFigure 2 in the Supplement).

Among the 243 V122I carriers, 0.8% (n = 2) were formally diagnosed with amyloidosis (ICD10 diagnosis "E85") compared with 0.1% (n = 5) of non-carriers. Both diagnosed patients were male heterozygous carriers, diagnosed at ages 75.9 and 71.9 years, respectively, and with cardiac manifestations of disease diagnosed during study follow-up. One of the 2 subjects died

during study follow-up with the primary cause of death being organ-limited amyloidosis (ICD10 diagnosis "E854").

Phenome-Wide Association Analysis

In a PHEWAS of the V122I variant in the unrelated Black UK Biobank subpopulation that included 427 ICD10 diagnosis codes, 1 significant association was identified, namely, the diagnosis of polyneuropathy (odds ratio [OR], 6.4, 95% confidence interval [CI], 2.6-15.6, $P = 4.2 \times 10^{-5}$) (Figure 1; eTable 1 in the Supplement). Significant associations between the V122I variant and polyneuropathy diagnosis were also seen in analyses of African Americans from the Penn Medicine Biobank (OR, 1.6, 95% CI, 1.2-2.4, $P = 6.0 \times 10^{-3}$) and the Million Veteran Program (OR, 1.5, 95% CI, 1.2-1.8, $P = 1.8 \times 10^{-4}$). In total, 2.1% (n = 5) of V122I carriers in the UK Biobank, 9.0% (n = 17) of V122I carriers in the Penn Medicine Biobank, and 4.8% (n = 111) of V122I carriers in the Million Veteran Program had a polyneuropathy diagnosis. The association of the V122I variant with polyneuropathy in the UK Biobank remained significant after adjustment for diabetes diagnosis (OR, 6.3, 95% CI, 2.6-15.4, $P = 6.4 \times 10^{-5}$).

The V122I Genotype and Risk of Common hATTR Amyloidosis Manifestations in the UK Biobank

Logistic regression demonstrated that the V122I genotype was significantly associated with having at least 1 common hATTR amyloidosis manifestation of either polyneuropathy, CTS, cardiomyopathy, or HF (OR, 2.66, $P = 1.5 \times 10^{-6}$). In total, 11.1% of V122I carriers had at least 1 common hATTR amyloidosis manifestation compared with 4.9% of non-carriers. Prevalence of

each of the 4 manifestations was higher in V122I carriers than non-carriers (eFigure 3 in the Supplement) and 2 of the 3 participants homozygous for V122I were diagnosed with at least 1 of the common hATTR amyloidosis manifestations (eFigure 4 in the Supplement). Significant associations between the V122I genotype and common hATTR amyloidosis manifestations were also observed in the Million Veteran Program (eTable 2 in the Supplement).

In Cox regression using UK Biobank data, the V122I genotype was significantly associated with time to first diagnosis of a common hATTR amyloidosis manifestation (hazard ratio [HR], 2.77, 95% CI, 1.72-4.47, $P = 2.62 \times 10^{-5}$; Figure 2). By age 65, the cumulative incidence of having at least 1 common hATTR amyloidosis manifestation among V122I carriers was 11.9% (95% CI, 3.1-19.8), which increased by age 75 to 37.4% (95% CI, 20.5-50.7), and was significantly higher than non-carriers (13.8%, 95% CI, 11.6-16).

The time to first common hATTR amyloidosis manifestation was assessed separately for each diagnosis (Figure 3; eTable 3 in the Supplement), finding V122I carriers had a significantly higher cumulative incidence of polyneuropathy, CTS, and HF than non-carriers (polyneuropathy HR, 6.9, $P = 9.5 \times 10^{-4}$; CTS HR, 2.7, $P = .01$; cardiomyopathy HR, 3.2, $P = .06$; HF HR, 3.2, $P = 2.0 \times 10^{-3}$). By age 75, 7.9% of V122I carriers had a polyneuropathy diagnosis, 13.2% had a CTS diagnosis, 2.5% had a cardiomyopathy diagnosis, and 16.7% had an HF diagnosis. Cardiomyopathy and HF tended to be more prevalent in V122I carriers than non-carriers at older ages (Figures 3C and 3D), whereas polyneuropathy was more prevalent at younger ages (Figure 3A).

Characteristics of V122I Carriers With Common hATTR Amyloidosis Manifestations in the UK Biobank

Multiple logistic regression demonstrated that V122I carriers with at least 1 common hATTR amyloidosis manifestation (n = 27) were more likely to be older and current/former cigarette smokers than those without common manifestations (n = 216). No sex difference was observed between those with and without any of the 4 common hATTR amyloidosis manifestations (*P* = .18) (eTable 4 in the Supplement).

Population Attributable Risk of Common hATTR Amyloidosis Manifestations to the V122I Variant

In the UK Biobank Black population, 16.7% of the risk of polyneuropathy diagnosis, 4.1% of the risk of a CTS diagnosis, 2.4% of the risk of a cardiomyopathy diagnosis, and 6.5% of the risk of a HF diagnosis was attributable to the V122I variant (Table 2).

Discussion

In this analysis of 3 large biobanks (UK Biobank, Penn Medicine Biobank, and the Million Veteran Program) including 2739 carriers, the V122I variant was significantly associated with a polyneuropathy diagnosis. This suggests that individuals with the V122I genotype, who were historically assumed to be predominantly at risk for cardiomyopathy, have a significantly increased risk of polyneuropathy. In the UK Biobank, by age 75, 7.9% of V122I carriers had a clinical diagnosis of polyneuropathy. Moreover, V122I carriers represent 1 in 5 of all

polyneuropathy diagnoses in this subpopulation of the UK Biobank. The V122I genotype has been linked to polyneuropathy in case reports and smaller studies[17-19] as well as highlighted within a recent scientific statement from the American Heart Association.[20] However, to our knowledge, this is the first study to show a significant association between the V122I genotype and polyneuropathy. Additionally, an overall enrichment of common hATTR amyloidosis manifestations (polyneuropathy, CTS, cardiomyopathy, and HF) was found among V122I carriers. Despite this clear enrichment, only 2 out of 243 patients were diagnosed with amyloidosis (ICD10 "E85"), suggesting a considerable underdiagnosis of the disease that is consistent with previous literature.[4,5] Notably, the 2 participants with confirmed amyloidosis were diagnosed in their 70s, with 1 dying from cardiac amyloid less than 2 years after diagnosis. This highlights the need for a better understanding of the early and multisystem manifestations of hATTR amyloidosis, particularly for V122I carriers who have higher mortality rates and worse prognosis than patients with other cardiac pathologies.[9,21-23]

To this end, the cumulative incidence of the 4 common hATTR amyloidosis manifestations was analyzed separately, finding V122I carriers had a significantly higher cumulative incidence of polyneuropathy, CTS, and HF than non-carriers. Moreover, V122I carriers were more likely than non-carriers to have polyneuropathy at a younger age and cardiac manifestations at older ages. This finding implies that diagnosing polyneuropathy may be key to earlier disease identification.

In order to identify the characteristics of participants with common hATTR amyloidosis manifestations, differences between V122I carriers with and without any diagnoses of the

common hATTR amyloidosis manifestations were analyzed. V122I carriers with these diagnoses were older and more likely to be current/former smokers. However, a difference between men and women in prevalence of common hATTR amyloidosis manifestations was not found, despite previous studies identifying gender as a significant modifier of disease penetrance.[24] While the 2 amyloidosis diagnoses were both in males, diagnoses of common hATTR amyloidosis manifestations were present in equal proportions of males and females.

The results are particularly important given recent advances in therapies for hATTR amyloidosis. Two major strategies have been employed: 1) reduce serum TTR levels by inhibiting hepatic synthesis of TTR proteins through RNA interference therapeutics (patisiran) or antisense oligonucleotides (inotersen); and 2) prevent dissociation of the TTR tetramer through small molecule TTR stabilizers (tafamidis). Both approaches have yielded positive results in phase 3 studies of hATTR amyloidosis with polyneuropathy[25,26] and tafamidis has also shown benefit in patients with ATTR amyloidosis with cardiomyopathy,[27] with studies underway for patisiran[28] and inotersen.[29] For patients with hATTR amyloidosis to derive maximal benefit from the available therapies, early identification of patients remains essential.

Previous studies of V122I carriers have captured patients late in their disease course and/or looked at a limited set of pre-defined outcomes.[30] The main strength of this study is its size and prospective nature. Moreover, we identify treatable clinical manifestations associated with carrying a variant common in individuals of African ancestry, who are historically understudied in genetic research.[31,32] However, this study must be interpreted in the context of potential limitations. Analyses in the UK Biobank were performed using inpatient hospital ICD10

diagnosis codes and do not capture outpatient or self-reported diagnoses. Therefore, it is possible our analyses missed additional hATTR amyloidosis manifestations present in participants but not captured in the hospital ICD10 diagnosis codes. Effect estimates of the association between the V122I variant and polyneuropathy were heterogeneous between the 3 biobanks (OR: UK Biobank = 6.4; Penn Medicine Biobank = 1.6; Million Veteran Program = 1.5). This is likely due to differences in the collection methods of ICD diagnosis codes: in the UK Biobank, diagnoses were from inpatient hospital records, whereas in the Penn Medicine Biobank and the Million Veteran Program they include both inpatient and outpatient diagnoses. Indeed, the rate of polyneuropathy in non-V122I carriers is lower in the UK Biobank, suggesting the higher odds ratio in this population may be due to the method of ICD10 diagnosis collection.

Additional limitations include that UK Biobank participants are healthier on average than the general UK population.[33] Also, despite the large sample size, the number of V122I carriers with common hATTR amyloidosis manifestations in the UK Biobank is small (n = 27), limiting statistical power to detect significant associations. Furthermore, V122I carriers in the UK Biobank were on average 60 years of age at censoring (range: 42-79 years), which is younger than the age range during which V122I hATTR amyloidosis typically presents.[30] We hypothesize that this younger age may be a reason that the well-known cardiac manifestations of hATTR amyloidosis are not as enriched as expected based on previous reports. Lastly, while 4 common hATTR amyloidosis manifestations were found to be enriched in V122I carriers, not all diagnoses of cardiomyopathy, CTS, HF, and polyneuropathy can be attributed to hATTR

amyloidosis since these are commonly seen with other diseases as well as in an idiopathic manner.

In a large unbiased study of 1 of the most common pathogenic *TTR* mutations, the V122I variant was significantly associated with polyneuropathy. This finding has important clinical implications as physicians should have a high clinical suspicion for the multisystem manifestations of hATTR amyloidosis in V122I carriers, including both cardiomyopathy and polyneuropathy.

ARTICLE INFORMATION

ACKNOWLEDGMENTS

This research has been conducted using the UK Biobank resource, application no. 26041. Funding was received from the Department of Veterans Affairs Office of Research and Development, Million Veteran Program (grant no. MVP003). This publication does not represent the views of the Department of Veterans Affairs or the US Government. This research was also supported by additional Department of Veterans Affairs awards (no. I01-BX003362 to Tsao and Chang) and used the resources and facilities at the VA Informatics and Computing Infrastructure (no. VA HSR RES 13-457 to Lynch). Damrauer is supported by the Veterans Administration (no. IK2-CX001780). Editorial assistance in the preparation of this manuscript was provided by Adelphi Communications Ltd, UK funded by Alnylam Pharmaceuticals. The authors would like to Katherine Alfond, PharmD, RPh of Alnylam Pharmaceuticals for her assistance in preparing this manuscript.

Author Contributions: Drs Parker, Damrauer, and Tcheandjieu had full access to the UK Biobank, Penn Medicine Biobank, and Million Veteran Program data analyzed in the study, respectively, and take responsibility for the integrity of the data and the accuracy of data analysis.

Concept and design: Fitzgerald, Vaishnaw, Hinkle, Nioi, Parker

Acquisition, analysis, or interpretation of data: Parker, Deaton, Ward, Flynn-Carroll, Damrauer, Tcheandjieu

All authors helped to interpret the data and critically revise the publication, are accountable for the accuracy and integrity of the publication, and provided final approval to submit for publication

Conflict of Interest Disclosures: Drs Parker, Erbe, Aldinc, Ticau, Fitzgerald, Vaishnaw, and A.O. Flynn-Carroll are employees and stockholders of Alnylam Pharmaceuticals. Drs Deaton, Ward, and Nioi are employees and stockholders of Alnylam Pharmaceuticals and former employees of Amgen Inc. Dr Hinkle is an employee and stockholder of Alnylam Pharmaceuticals, reports personal fees from 54gene and has a patent US8168775B2 issued. Dr Damrauer reports grants from U.S. Department of Veterans Affairs and RenalytixAI, and personal fees from Calico Labs. Dr Hawkins reports personal fees from Alnylam Pharmaceuticals. Dr Gillmore reports grants and personal fees from Alnylam Pharmaceuticals, and personal fees from Akcea and Eidos Therapeutics. Dr Lynch is an employee with the federal government, Department of Veterans Affairs, and has received grants from the Department of Veteran Affairs. Dr Joseph has received research grants from U.S. Department of Veteran Affairs Office of Research and Development, Novartis, Kowa, Otsuka, and Amgen. Dr Tsao reports grants from U.S. Department of Veteran

Affairs Office of Research and Development. Dr Chang is an employee with the federal

government, Department of Veterans Affairs, has research funding from the Department of

Veteran Affairs, and serves on the scientific advisory board for Arbutus, Inc. Dr Rader reports

personal fees from Alnylam Pharmaceuticals, Novartis, and Pfizer. Drs Tcheandjieu, Hull, and

Assimes have nothing to disclose.

Funding/Support: Analysis of the UK Biobank data is funded by Alnylam Pharmaceuticals Inc. Dr

Damrauer is supported by the U.S. Department of Veterans Affairs (IK2-CX001780). Analysis of

the VA Million Veteran Program data is supported by the U.S. Department of Veterans Affairs

(I01-BX003362I and VA HSR RES 13-457). This publication does not represent the views of the

U.S. Department of Veterans Affairs or the U. S. Government.

REFERENCES

1.   Hanna M. Novel drugs targeting transthyretin amyloidosis. *Curr Heart Fail Rep.* 2014;11(1):50-57. doi:10.1007/s11897-013-0182-4

2.   Mohty D, Damy T, Cosnay P, et al. Cardiac amyloidosis: updates in diagnosis and management. *Arch Cardiovasc Dis.* 2013;106(10):528-540. doi:10.1016/j.acvd.2013.06.051

3.   Adams D, Coelho T, Obici L, et al. Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. *Neurology.* 2015;85(8):675-682. doi:10.1212/WNL.0000000000001870

4.   Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. *N Engl J Med.* 1997;336(7):466-473. doi:10.1056/nejm199702133360703

5.   Damrauer SM, Chaudhary K, Cho JH, et al. Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic/Latino ancestry. *JAMA.* 2019;322(22):2191-2202. doi:10.1001/jama.2019.17935

6.   Jacobson DR, Alexander AA, Tagoe C, et al. The prevalence and distribution of the amyloidogenic transthyretin (*TTR*) V122I allele in Africa. *Mol Genet Genomic Med.* 2016;4(5):548-556. doi:10.1002/mgg3.231

7.   Dharmarajan K, Maurer MS. Transthyretin cardiac amyloidoses in older North Americans. *J Am Geriatr Soc.* 2012;60(4):765-774. doi:10.1111/j.1532-5415.2011.03868.x

8.   Gorevic PD, Prelli FC, Wright J, Pras M, Frangione B. Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: immunologic and biochemical

similarity to one form of familial amyloidotic polyneuropathy. *J Clin Invest.* 1989;83(3):836-843.

doi:10.1172/jci113966

9. Dungu JN, Papadopoulou SA, Wykes K, et al. Afro-Caribbean heart failure in the United Kingdom: cause, outcomes, and ATTR V122I cardiac amyloidosis. *Circ Heart Fail.* 2016;9(9):e003352. doi:10.1161/CIRCHEARTFAILURE.116.003352

10. Buxbaum J, Jacobson DR, Tagoe C, et al. Transthyretin V122I in African Americans with congestive heart failure. *J Am Coll Cardiol.* 2006;47(8):1724-1725. doi:10.1016/j.jacc.2006.01.042

11. Conceição I, Damy T, Romero M, et al. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. *Amyloid.* 2019;26:1-7. doi:10.1080/13506129.2018.1556156

12. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med.* 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779

13. Allen N, Sudlow C, Downey D, et al. UK Biobank: current status and what it means for epidemiology. *Health Policy Technol.* 2012;1(3):123-126. doi:10.1016/j.hlpt.2012.07.003

14. Gaziano JM, Concato J, Brophy M, et al. Million veteran program: a mega-biobank to study genetic influences on health and disease. *J Clin Epidemiol.* 2016;70:214-223. doi:10.1016/j.jclinepi.2015.09.016

15. The UK Biobank. UK Biobank axiom array: content summary. Published 2014. Accessed.

    http://www.ukbiobank.ac.uk/wp-content/uploads/2014/04/UK-Biobank-Axiom-Array-Content-

    Summary-2014-1.pdf.

16. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to

    the challenge of larger and richer datasets. *Gigascience.* 2015;4:7. doi:10.1186/s13742-015-

    0047-8

17. Carr AS, Pelayo-Negro AL, Jaunmuktane Z, et al. Transthyretin V122I amyloidosis with clinical

    and histological evidence of amyloid neuropathy and myopathy. *Neuromuscul Disord.*

    2015;25(6):511-515. doi:10.1016/j.nmd.2015.02.001

18. Ammirati E, Marziliano N, Vittori C, et al. The first Caucasian patient with p.Val122Ile mutated-

    transthyretin cardiac amyloidosis treated with isolated heart transplantation. *Amyloid.*

    2012;19(2):113-117. doi:10.3109/13506129.2012.666509

19. Nichols WC, Liepnieks JJ, Snyder EL, Benson MD. Senile cardiac amyloidosis associated with

    homozygosity for a transthyretin variant (ILE-122). *J Lab Clin Med.* 1991;117(3):175-180. doi.

20. Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolving diagnosis and

    management: a scientific statement from the American Heart Association. *Circulation.*

    2020;142(1):e7-e22. doi:10.1161/cir.0000000000000792

21. Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in

    cardiac transthyretin amyloidosis. *Circulation.* 2019;140(1):16-26.

    doi:10.1161/circulationaha.118.038169

22. Polimanti R, Nuñez YZ, Gelernter J. Increased risk of multiple outpatient surgeries in African-American carriers of transthyretin Val122Ile mutation is modulated by non-coding variants. *J Clin Med.* 2019;8(2):269. doi:10.3390/jcm8020269

23. Ruberg FL, Maurer MS, Judge DP, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). *Am Heart J.* 2012;164(2):222-228 e221. doi:10.1016/j.ahj.2012.04.015

24. Connors LH, Prokaeva T, Lim A, et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. *Am Heart J.* 2009;158(4):607-614. doi:10.1016/j.ahj.2009.08.006

25. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. *N Engl J Med.* 2018;379(1):11-21. doi:10.1056/NEJMoa1716153

26. Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. *N Engl J Med.* 2018;379(1):22-31. doi:10.1056/NEJMoa1716793

27. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. *N Engl J Med.* 2018;379(11):1007-1016. doi:10.1056/NEJMoa1805689

28. Alnylam Pharmaceuticals Inc. *Clinical trial: APOLLO-B: a study to evaluate patisiran in participants with transthyretin amyloidosis with cardiomyopathy (ATTR amyloidosis with cardiomyopathy).* ClinicalTrial.gov2019. NCT03997383.

29.   Brigham and Women's Hospital. *Clinical trial: 24 month open label study of the tolerability and efficacy of intersen in TTR amyloid cardiomyopathy patients.* ClinicalTrials.gov2019. NCT03702829.

30.   Buxbaum JN, Ruberg FL. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. *Genet Med.* 2017;19(7):733-742. doi:10.1038/gim.2016.200

31.   Sirugo G, Williams SM, Tishkoff SA. The missing diversity in human genetic studies. *Cell.* 2019;177(1):26-31. doi:10.1016/j.cell.2019.02.048

32.   Popejoy AB, Fullerton SM. Genomics is failing on diversity. *Nature.* 2016;538(7624):161-164. doi:10.1038/538161a

33.   Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. *Am J Epidemiol.* 2017;186(9):1026-1034. doi:10.1093/aje/kwx246

Table 1. Baseline Characteristics of the Black UK Biobank Study Population (n = 6062) by V122I Genotype

	Non-carriers (GG) (n = 5819)	Carriers (GA or AA) (n = 243)	*P*
Mean (SD) age at enrollment (years)	51.9 (8.1)	52.6 (8.2)	.22
Male (%)	42.7	46.5	.27
Mean (SD) BMI, kg/m^2	29.6 (5.4)	29.7 (5.1)	.76
Hypertension (%)	36.8	39.7	.39
Diabetes (%)	11.3	12.1	.95
Smoking (%)	27.8	27.2	.99

Abbreviations: BMI, body mass index; SD, standard deviation.

Table 2. Attributable Risk of Common hATTR Amyloidosis Manifestations in the UK Biobank Black Population (n = 6062) Due to the V122I Variant

	Diagnoses in V122I carriers, % (n/N)	Population attributable risk to V122I variant, %
Polyneuropathy	20.0 (5/25)	16.7
CTS	7.5 (13/174)	4.1
Cardiomyopathy	7.5 (3/40)	2.4
HF	10.2 (10/98)	6.5
At least 1 common hATTR amyloidosis manifestation	8.7 (27/311)	5.5

Abbreviations: CTS, carpal tunnel syndrome; hATTR, hereditary transthyretin-mediated; HF, heart failure.

FIGURE LEGENDS

Figure 1. Phenome-Wide Association Study of the V122I Variant and 427 ICD10 Diagnosis Codes in the Black UK Biobank Population

The dotted gray line indicates a multiple comparison-corrected significance cutoff of $P < 1.2 \times 10^{-4}$.

Figure 2. Cumulative Incidence of Common hATTR Amyloidosis Manifestations by V122I Genotype in the UK Biobank (HR, 2.77, $P = 2.62 \times 10^{-5}$)

CI indicates confidence interval; hATTR, hereditary transthyretin-mediated; HR, hazard ratio.

Figure 3. Cumulative Incidence by V122I Genotype of First Diagnosis of Common hATTR Amyloidosis Manifestation

Panel A: Polyneuropathy (G62); Panel B: Carpal Tunnel Syndrome (G560); Panel C: Cardiomyopathy (I42); and Panel D: Heart Failure (I50 or I098).

Figure 1

Figure 2

Cumulative incidence of common hATTR amyloidosis manifestations:	50	55	60	65	70	75
V122I carriers (95% CI)	0.0% (0.0-0.0)	2.1% (0.0-6.8)	7.0% (1.4-12.4)	11.9% (3.1-19.8)	20.6% (6.9-30.9)	37.4% (20.5-50.7)
Non-carriers (95% CI)	1.7% (0.8-2.5)	3.3% (2.3-4.2)	5.2% (4.1-6.4)	7.8% (6.3-9.2)	9.6% (8.0-11.2)	13.8% (11.6-16.0)

Figure 3

Supplementary Online Content

Parker MM, Damrauer SM, Tcheandjieu C, et al. Association of the Transthyretin Variant V122I With Polyneuropathy Among Individuals of African Descent. *JAMA*. Published TBC by publishers

Supplementary eAppendix 1. Additional Methodologic Details

eFigure 1. Genetic Principal Component 1 Versus Genetic Principal Component 2 With V122I Carriers Highlighted (Red). The Majority (80.6%) of V122I Carriers Are of African Ancestry. The MAF of V122I in the 4 UK Biobank Subpopulations Was: 1) MAF Black Subpopulation = 0.02; 2) MAF White Subpopulation = 1.78×10^{-5}; 3) MAF Southeast Asian Subpopulation = 0.0; 4) MAF Chinese Subpopulation = 0.0

eFigure 2. Histograms of Panel A: Follow-Up Time in Unrelated Black Participants of the UK Biobank Study (Mean 7.6 Years, Range: 0.22-10.0 Years) and Panel B: Age at Last Known UK Biobank Observation (Mean 59.6 Years, Range: 42.2-79.0 Years). Censoring Occurred at Date of Death (if Died), Date of Loss to Follow-Up (if Lost to Follow-Up), or March 31, 2017, for Participants in England, February 29, 2016, for Participants in Wales, or October 31, 2016, for Participants in Scotland. UK Biobank Participants in This Study Were Followed for a Total of 46 260.8 Years of Person-Time

eFigure 3. Prevalence of Diagnoses Frequently Associated with hATTR Amyloidosis in V122I Carriers and Non-carriers

eFigure 4. Descriptive Analysis of 3 Homozygous V122I Carriers, Including Demographic Information and All ICD10 Diagnosis Codes and Operations during Study Follow-Up

eTable 1. Top Results from the Phenome-Wide Association Analysis of V122I Variant and ICD10 Diagnosis Codes in the Unrelated Black Population of the UK Biobank

eTable 2. Association of the V122I Variant With hATTR Amyloidosis Diagnosis and Common hATTR Amyloidosis Manifestations in the Million Veteran Program Cohort (n = 2306 V122I carriers and 80 076 non-carriers). Results Are from a Logistic Regression Controlling for Age, Sex, and Genetic Ancestry via the First 10 Principal Components

eTable 3. Cumulative Incidence of Common hATTR Amyloidosis Manifestations by Age. Estimates from Kaplan–Meier Analysis Testing Time to First Common hATTR Amyloidosis Manifestation by V122I Genotype during UK Biobank Study Follow-Up. Prevalent Diagnoses Occurring before a Patient's Date of Enrollment Were Removed. The Association of V122I Genotype With Time to First Common Manifestation Is Tested Using Cox Proportional Hazards Regression Controlling for Age, Sex, Smoking, and Genetic Ancestry via 10 Genetic Principal

Components (Polyneuropathy HR, 6.9, 95% CI, 2.2-21.7, P = 9.5×10^{-4}; Carpal Tunnel Syndrome HR, 2.7, 95% CI, 1.2-5.8, P = .01; Cardiomyopathy HR, 3.2, 95% CI, 0.9-10.7, P = .06; Heart Failure HR, 3.2, 95% CI, 1.5-6.9, P = .002)

eTable 4. Characteristics of V122I Carriers With ≥1 Diagnosis of a Common hATTR Amyloidosis Manifestation (Polyneuropathy, Carpal Tunnel Syndrome, Cardiomyopathy, and Heart Failure)

eAppendix: Additional Methodologic Details

Study Populations

UK Biobank

The UK Biobank is a large population-based prospective cohort study which recruited 502 634 participants aged 40-69 years in England, Wales, and Scotland between 2006 and 2010.[1] Participants in the UK Biobank lived within 25 miles of 1 of the 22 assessment centers and participated in a baseline assessment involving the collection of extensive data from questionnaires, health records, physical measurements, imaging, and biologic samples.[1] The UK Biobank recruited a population-based sample without selection on any disease outcome, but subjects were generally healthier than the overall National Health Service (NHS) population at baseline.[2] Data used in this analysis were accessed through UK Biobank application no. 26041 and are publicly available upon request to the UK Biobank.

This analysis included 6062 participants in the unrelated Black population of the UK Biobank, defined based on a combination of self-reported ancestry and genetic principal components (based on "British white" subset defined in Bycroft et al.[3]). To define the Black population, the R package aberrant[4] (lambda value = 40) was run on genetic principal components 1-6 provided by the UK Biobank to isolate the largest cluster of participants while excluding population outliers. Principal component analysis on the remaining subset using PLINK v.2.0[5] identified the principal components used as covariates to control for population stratification.

All UK Biobank study participants underwent a baseline study assessment where covariates including age, sex, body mass index, self-reported diabetes diagnosis, self-reported hypertension diagnosis, and smoking status were collected. Additionally, participants consented to access to their NHS hospital records, which were used to obtain primary and secondary International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD10) disease diagnosis codes. Diagnosis codes were collected prospectively from inpatient NHS visits during study follow-up and retrospectively from 1996 to baseline visit.

Penn Medicine Biobank

The Penn Medicine Biobank currently includes over 60 000 participants enrolled through the University of Pennsylvania Health System who have consented to allow the linkage of biospecimens to their longitudinal electronic health record (EHR). The current analysis utilizes data on 5 737 individuals of genetically inferred African ancestry recruited between November 21, 2008 and January 4, 2017 that passed quality control as described in detail elsewhere.[6]

Million Veteran Program

The Million Veteran Program is a large multi-ethnic cohort within the United States Department of Veterans Affairs (VA). Since 2011, more than 825 000 veterans over age 18 years have been recruited from 63 participating VA medical center facilities across the United States.[7] The Million Veteran Program biobank incorporates data from biospecimens, baseline and lifestyle surveys, and EHRs, including clinical laboratory measurements, diagnostic imaging reports, diagnosis, and procedure codes and vital status. Million Veteran Program research protocols

were approved by the VA Central Institutional Review Board. All participants provided informed consent and authorization for review of their medical records.

For this analysis, genotyped and imputed genetic information was available for 468 961 multi-ethnic participants enrolled in the Million Veteran Program between 2011 and 2017, among which 87 163 participants are of HARE assigned African ancestry.[8] Million Veteran Program EHR data do not include information from Medicare claims.

V122I Genotyping

UK Biobank participants were genotyped on either the UK BiLEVE or UK Biobank Axiom array,[9] which share >95% common content. Genotypic data were imputed to the UK10K haplotype, 1000 Genomes phase 3, and Haplotype Reference Consortium reference panels using SHAPEIT3[10] for phasing and IMPUTE4[3] for imputation. The V122I variant was directly genotyped on both arrays (info score = 1) and passed all quality control metrics (Hardy–Weinberg equilibrium $P = 7.2 \times 10^{-5}$, genotyping call rate = 100%).

Phenome-Wide Association Analysis and Replication

Phenome-wide association analysis was performed in PLINK (v2.0)[5] using logistic regression with the "firth-fallback" option, which runs Firth regression[11] when logistic regression fails due to a rare outcome. Analyses were performed using the REVEAL/SciDB translational analytics platform from Paradigm4. The significant association between the V122I variant and polyneuropathy diagnosis was replicated in the Penn Medicine Biobank and the Million Veteran Program. In the Penn Medicine Biobank, polyneuropathy was defined as the assignment of the

ICD9 diagnosis code 357 or ICD10 diagnosis codes of G62 or G63 on two or more separate dates. Association was assessed using logistic regression, controlling for age, sex, and the first 5 principal components. In the Million Veteran Program, polyneuropathy was defined as a diagnosis of "G62," including child codes. Association was assessed using logistic regression, controlling for age, sex, and the first 10 principal components of genetic ancestry in 82 362 unrelated Million Veteran Program participants of African ancestry.

Assessment of Common hATTR Amyloidosis Manifestations in V122I Carriers

Time to first diagnosis of common hereditary transthyretin-mediated (hATTR) amyloidosis manifestations (polyneuropathy ["G62"], carpal tunnel syndrome ["G560"], cardiomyopathy ["I42"], or heart failure ["I50" or "I098"]) was tested in the UK Biobank unrelated Black population. For time to event analyses, prevalent diagnoses occurring before a patient's date of enrollment were removed. Time on study was calculated as date of enrollment to date of first primary or secondary diagnosis of an hATTR amyloidosis manifestation (if participant had a diagnosis), date of lost to follow-up (if participant was lost to follow-up), or date of administrative censoring (March 31, 2017, for participants in England, February 29, 2016, for participants in Wales, or October 31, 2016, for participants in Scotland). Age at diagnosis was calculated from month and year of birth. Data availability dates were obtained from: http://biobank.ctsu.ox.ac.uk/crystal/exinfo.cgi?src=Data_providers_and_dates (accessed on: April 1, 2019). Survival analyses were performed in R version 3.4.4 using the survival (v. 2.43) and survminer packages (v. 0.4.3). All analyses were controlled for known confounders including age, sex, smoking status, and genetic ancestry via 10 genetic principal components.

Population Attributable Risk to the V122I Variant

The population attributable risk of common hATTR amyloidosis manifestations due to the V122I variant was calculated in the unrelated Black subpopulation of the UK Biobank (n = 6062). The following equation was used, where risk was estimated using the cumulative incidence of disease at age 75 from the Kaplan–Meier curve.

$$Population\ attributable\ risk = \frac{N\ V122I\ with\ disease}{N\ total\ with\ disease} \times \frac{CI\ V122I - CI\ Non-carrier}{CI\ V122I}$$

CI indicates cumulative incidence.

eFigure 1. Genetic Principal Component 1 Versus Genetic Principal Component 2 With V122I Carriers Highlighted (Red). The Majority (80.6%) of V122I Carriers Are of African Ancestry. The MAF of V122I in the 4 UK Biobank Subpopulations Was: 1) MAF Black Subpopulation = 0.02; 2) MAF White Subpopulation = 1.78×10^{-5}; 3) MAF Southeast Asian Subpopulation = 0.0; 4) MAF Chinese Subpopulation = 0.0

MAF indicates minor allele frequency.

eFigure 2. Histograms of Panel A: Follow-Up Time in Unrelated Black Participants of the UK

Biobank Study (Mean 7.6 Years, Range: 0.22-10.0 Years) and Panel B: Age at Last Known UK

Biobank Observation (Mean 59.6 Years, Range: 42.2-79.0 Years). Censoring Occurred at Date of

Death (if Died), Date of Loss to Follow-Up (if Lost to Follow-Up), or March 31, 2017, for

Participants in England, February 29, 2016, for Participants in Wales, or October 31, 2016, for

Participants in Scotland. UK Biobank Participants in This Study Were Followed for a Total of

46 260.8 Years of Person-Time

eFigure 3. Prevalence of Diagnoses Frequently Associated with hATTR Amyloidosis

in V122I Carriers and Non-carriers

hATTR indicates hereditary transthyretin-mediated.

eFigure 4. Descriptive Analysis of 3 Homozygous V122I Carriers, Including Demographic

Information and All ICD10 Diagnosis Codes and Operations during Study Follow-Up

NEC indicates not elsewhere classified.

Homozygote #1
Male, Age 54

M77.47 Metatarsalgia—ankle/foot
M70.22 Olecranon bursitis—upper arm
M25.57 Pain in joint (ankle and foot)
R31 Unspecified hematuria
N32.0 Bladder—neck obstruction
G62.9 Polyneuropathy, unspecified
Z72.0 Tobacco use
R93.6 Abnormal findings on diagnostic imaging of limbs
I10 Essential (primary) hypertension
R39.1 Other difficulties with micturition
R33 Retention of urine
N40 Hyperplasia of prostate
W15.9 Unspecified division of bone of foot
W09.1 Excision of lesion of bone NEC
W08.5 Partial excision of bone NEC
M65.3 Endoscopic resection of prostate NEC
M47.9 Unspecified urethral catheterization of bladder
M45.9 Unspecified diagnostic endoscopic examination of bladder
A55.9 Unspecified diagnostic spinal puncture

Homozygote #2
Male, Age 69

R33 Retention of urine
C61 Malignant neoplasm of prostate
K22.2 Esophageal obstruction
G56.0 Carpal tunnel syndrome
R33 Retention of urine
N39.0 Urinary tract infection, site not specified
B96.2 *Escherichia Coli (E. Coli)* as the cause of diseases classified to other chapters
X99.8 No procedure performed
G45.9 Unspecified diagnostic fiberoptic endoscopic examination of upper gastrointestinal tract
G44.3 Fiberoptic endoscopic dilation of upper gastrointestinal tract NEC
A65.1 Carpal tunnel release

Homozygote #3
Female, Age 69

H26.9 Cataract, unspecified
H25.9 Senile cataract, unspecified
D25.9 Leiomyoma of uterus, unspecified
Z86.7 Personal history of diseases of the circulatory System
I10 Essential (primary) hypertension
C75.1 Insertion of prosthetic replacement for lens NEC
U21.2 Computed tomography NEC

eTable 1. Top Results from the Phenome-Wide Association Analysis of V122I Variant and ICD10 Diagnosis Codes in the Unrelated Black Population of the UK Biobank

ICD10 diagnosis code	Odds ratio	Standard error	P
Polyneuropathy (G62)	6.40	0.45	4.24×10^{-5}
Other disorders of synovium and tendon (M67)	3.22	0.34	5.40×10^{-4}
Unspecified lump in breast (N63)	5.29	0.50	7.80×10^{-4}
Epididymitis (N45)	6.54	0.56	8.66×10^{-4}
Heart failure (I50)	2.50	0.32	4.35×10^{-3}
Unspecified right bundle-branch block (I45)	3.67	0.47	5.60×10^{-3}
Retention of urine (R33)	2.52	0.34	6.36×10^{-3}
Mononeuropathies of upper limb (G56)	1.94	0.29	1.98×10^{-2}
Postprocedural disorders of digestive system (K91)	4.20	0.62	2.03×10^{-2}
Overexertion and strenuous or repetitive movements (X50)	3.82	0.62	2.95×10^{-2}
Non-rheumatic mitral value insufficiency (I34)	3.00	0.51	3.09×10^{-2}
Other enthesopathies (M77)	3.53	0.60	3.68×10^{-2}
Ascites (R18)	2.93	0.52	3.99×10^{-2}
Other dermatitis (L30)	3.33	0.60	4.63×10^{-2}
Umbilical hernia (K42)	2.04	0.37	5.17×10^{-2}

Abbreviation: ICD10 indicates International Statistical Classification of Diseases and Related Health Problems, 10th Revision

eTable 2. Association of the V122I Variant With hATTR Amyloidosis Diagnosis and Common hATTR Amyloidosis Manifestations in the Million Veteran Program Cohort (n = 2306 V122I Carriers and 80 076 Non-Carriers). Results Are from a Logistic Regression Controlling for Age, Sex, and Genetic Ancestry Via the First 10 Principal Components

	Cases	Controls	Odds ratio	95% confidence interval	P
Amyloidosis	869	81 513	1.90	1.38-2.62	9.49×10^{-5}
Cardiomyopathy	3967	78 415	1.34	1.12-1.61	1.42×10^{-3}
Carpal tunnel syndrome	4711	77 671	1.69	1.45-1.97	1.95×10^{-11}
Heart failure	8717	73 665	1.32	1.16-1.51	2.82×10^{-5}
Polyneuropathy	2745	79 637	1.48	1.21-1.82	1.79×10^{-4}

Abbreviation: hATTR indicates hereditary transthyretin-mediated.

eTable 3. Cumulative Incidence of Common hATTR Amyloidosis Manifestations by Age. Estimates from Kaplan–Meier Analysis Testing Time to First Common hATTR Amyloidosis Manifestation by V122I Genotype during UK Biobank Study Follow-Up. Prevalent Diagnoses Occurring before a Patient's Date of Enrollment Were Removed. The Association of V122I Genotype With Time to First Common Manifestation Is Tested Using Cox Proportional Hazards Regression Controlling for Age, Sex, Smoking, and Genetic Ancestry via 10 Genetic Principal Components (Polyneuropathy HR, 6.9, 95% CI, 2.2-21.7, P = 9.5×10^{-4}; Carpal Tunnel Syndrome HR, 2.7, 95% CI, 1.2-5.8, P = .01; Cardiomyopathy HR, 3.2, 95% CI, 0.9-10.7, P = .06; Heart Failure HR, 3.2, 95% CI, 1.5-6.9, P = .002)

Age	Cumulative incidence V122I carriers (95% CI)	Cumulative incidence non-carriers (95% CI)
Polyneuropathy		
50	0.0% (0.0-0.0)	0.0% (0.0-0.0)
55	0.0% (0.0-0.0)	0.2% (0.0-0.4)
60	0.0% (0.0-0.0)	0.3% (0.1-0.5)
65	5.6% (0.0-11.8)	0.6% (0.2-0.9)
70	7.9% (0.0-15.2)	0.6% (0.2-0.9)
75	7.9% (0.0-15.2)	1.3% (0.5-2.1)
Carpal tunnel syndrome		
50	0.0% (0.0-0.0)	0.2% (0.0-0.3)
55	1.2% (0.0-3.4)	1.0% (0.6-1.4)
60	1.2% (0.0-3.4)	2.0% (1.4-2.6)
65	5.4% (0.0-11.4)	3.9% (3.0-4.9)
70	9.9% (1.0-17.9)	4.6% (3.5-5.7)
75	13.2% (2.2-23.0)	6.0% (4.6-7.5)
Cardiomyopathy		
50	0.0% (0.0-0.0)	0.0% (0.0-0.0)
55	0.0% (0.0-0.0)	0.2% (0.0-0.4)
60	0.0% (0.0-0.0)	0.7% (0.3-1.0)
65	0.0% (0.0-0.0)	1.1% (0.6-1.7)
70	0.0% (0.0-0.0)	1.3% (0.7-2.0)
75	2.5% (0.0-7.2)	1.7% (0.9-2.4)
Heart failure		

50	0.0% (0.0-0.0)	0.2% (0.0-0.3)
55	1.1% (0.0-3.1)	1.0% (0.6-1.4)
60	1.1% (0.0-3.1)	2.0% (1.4-2.6)
65	1.1% (0.0-3.1)	3.9% (3.0-4.9)
70	1.1% (0.0-3.1)	4.6% (3.5-5.7)
75	16.7% (1.1-29.8)	6.0% (4.6-7.5)

Abbreviations: CI indicates confidence interval, hATTR, hereditary transthyretin-mediated; HR, hazard ratio.

eTable 4. Characteristics of V122I Carriers With ≥1 Diagnosis of a Common hATTR Amyloidosis Manifestation (Polyneuropathy, Carpal Tunnel Syndrome, Cardiomyopathy, and Heart Failure)

	No common manifestations (n = 216)	At least 1 common manifestation (n = 27)	*P*
Mean (SD) age, years	51.70 (7.75)	61.00 (7.80)	2.81×10^{-6}
Male (%)	47.70	37.00	.18
Mean (SD) BMI, kg/m^2	29.60 (5.03)	30.90 (5.88)	.35
Smoking (%)	25.50	40.70	.014
Genetic PC 1	384.00 (29.10)	384.00 (33.10)	.89

Abbreviations: BMI indicates body mass index; PC, principal component; SD, standard deviation.

eReferences

1. Allen N, Sudlow C, Downey D, et al. UK Biobank: current status and what it means for epidemiology. *Health Policy Technol.* 2012;1(3):123-126.

2. Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. *Am J Epidemiol.* 2017;186(9):1026-1034. doi: 10.1093/aje/kwx246

3. Bycroft C, Freeman C, Petkova D, et al. Genome-wide genetic data on ~500,000 UK Biobank participants. BioRxiv. Published July 2017. Accessed . https://www.biorxiv.org/content/10.1101/166298v1

4. Bellenguez C, Strange A, Freeman C, Wellcome Trust Case Control Consortium, Donnelly P, Spencer CC. A robust clustering algorithm for identifying problematic samples in genome-wide association studies. *Bioinformatics.* 2012;28(1):134-135. doi: 10.1093/bioinformatics/btr599

5. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience.* 2015;4:7. doi: 10.1186/s13742-015-0047-8

6. Damrauer SM, Chaudhary K, Cho JH, et al. Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic/Latino ancestry. *JAMA.* 2019;322(22):2191-2202. doi: 10.1001/jama.2019.17935

7. Gaziano JM, Concato J, Brophy M, et al. Million veteran program: a mega-biobank to study genetic influences on health and disease. *J Clin Epidemiol.* 2016;70:214-223. doi: 10.1016/j.jclinepi.2015.09.016

8.   Fang H, Hui Q, Lynch J, et al. Harmonizing genetic ancestry and self-identified race/ethnicity in genome-wide association studies. *Am J Hum Genet*. 2019;105(4):763-772.

9.   The UK Biobank. UK Biobank axiom array: content summary. Published 2014. Accessed . http://www.ukbiobank.ac.uk/wp-content/uploads/2014/04/UK-Biobank-Axiom-Array-Content-Summary-2014-1.pdf

10.   O'Connell J, Sharp K, Shrine N, et al. Haplotype estimation for biobank-scale data sets. *Nat Genet*. 2016;48(7):817-820. doi: 10.1038/ng.3583

11.   Wang X. Firth logistic regression for rare variant association tests. *Front Genet*. 2014;5:187. doi: 10.3389/fgene.2014.00187